FINANCE/FUNDING ARTICLES

  • The Rollercoaster Ride Of A Biotech CEO
    The Rollercoaster Ride Of A Biotech CEO

    Sam Cobb, managing director and CEO of Australian biotech AdAlta, talks about how the company has struggled to procure funding over the years and the strategies they employed to finally get listed on the Australian Securities Exchange.

  • Paving The Way For Future Funding
    Paving The Way For Future Funding

    Growing a life sciences company will have continuous demands for funding. Wherever that money comes from, undertaking a commitment to PCAOB (Public Company Accounting Oversight Board) compliance will be valued by potential investors.

  • The Drug-Delivery Company That Partnerships Built
    The Drug-Delivery Company That Partnerships Built

    “Normally a company raises money, does their science, and hopes to get a deal. We were the inverse of that,” explains Joseph Payne, president and CEO of Arcturus Therapeutics.

  • Is China’s Golden Era Ending?
    Is China’s Golden Era Ending?

    The value of China’s biotechs fell some 30 percent since the trade war began, and VC funding, while strong, slipped before that. Interest in China, however, remains strong.

  • How Biopharma & Medtech CFOs Are Viewing U.S. Tax Reform
    How Biopharma & Medtech CFOs Are Viewing U.S. Tax Reform

    Biopharma and medtech companies are expecting mostly positive results from the new Tax Cuts and Jobs Act (TCJA), according to research by The Deloitte Center for Health Solutions and Forbes Insights.

  • How To Put A Price Tag On Emerging Therapies
    How To Put A Price Tag On Emerging Therapies

    There’s no doubt that partnerships and M&As are key growth drivers in the biopharma industry.  But for collaborative relationships to occur, understanding the value of a company’s underlying assets is critical.

  • Serendipity: When Funders Found A Company
    Serendipity: When Funders Found A Company

    Foghorn Therapeutics is managing to sidestep some of the growing pains common to early companies, thanks to its genesis as a VC-founded company.

  • When Should Tax Functions Be Brought In-House?
    When Should Tax Functions Be Brought In-House?

    At what stage of a biopharma’s growth does it makes sense to bring on an internal tax function? The answer, of course, varies significantly, but here are some factors to consider when making this important business decision.

  • Recent Changes May Reshape Financial Reporting In The Life Sciences Industry
    Recent Changes May Reshape Financial Reporting In The Life Sciences Industry

    Changes to the accounting standards that affect matters like revenue recognition, the definition of a business, and leases could significantly affect the accounting for certain transactions in the life sciences industry.

  • Biopharma Startups Take Advantage Of Open IPO Window
    Biopharma Startups Take Advantage Of Open IPO Window

    Biopharma startups are enjoying a window of opportunity for successful IPOs that opened in mid-2017. CEOs share their experiences of going public, what is fueling IPOs, and tips for others thinking about making this important next step.

More finance/funding articles